HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Granulomatosis with polyangiitis — Clinical Guidelines

Overview

Granulomatosis with polyangiitis (GPA) is an ANCA-associated vasculitis characterized by necrotizing granulomatous inflammation and pauci-immune vasculitis affecting small to medium-sized blood vessels, commonly impacting the upper respiratory tract, lungs, kidneys, and other organs 1 2 3.

Diagnosis

Key Criteria: Presence of antineutrophil cytoplasmic antibodies (ANCA), clinical features including respiratory tract involvement, renal manifestations, and other organ involvement 4 5.

Recommended Tests: ANCA testing (PR3-ANCA or MPO-ANCA), imaging studies (CT, MRI), and histopathologic examination 4 6.

Classification Criteria: 2022 ACR/EULAR criteria outperform 2008 EULAR/PRINTO/PReS criteria in pediatric patients 1.

Performance: Validation of 2022 criteria across diverse populations, including pediatric and adult patients, showing robust performance 4 6.

Management

First-Line Treatments: High-dose glucocorticoids (e.g., prednisone) combined with immunosuppressive agents such as rituximab or cyclophosphamide 4 6.

Adjunctive Treatments: Maintenance therapy with rituximab, azathioprine, or mycophenolate mofetil to prevent relapse 8 9.

Specific Doses: Rituximab typically administered as 375 mg/m2 intravenously twice weekly for four doses 8.

Monitoring: Regular ANCA testing, clinical assessments, and organ function monitoring to manage disease activity and side effects 4.

Special Populations

Pediatrics: 2022 ACR/EULAR criteria show improved performance compared to older pediatric criteria 1.

Comorbidities: Specific management considerations for patients with systemic manifestations like parotid gland involvement or atypical presentations (e.g., acne fulminans) require multidisciplinary care 8 12 14.

Elderly: Tailored immunosuppressive strategies considering age-related comorbidities and renal function 4.

Key Recommendations

Use the 2022 ACR/EULAR classification criteria for GPA diagnosis, especially in pediatric patients, to improve diagnostic accuracy 1 (Evidence: Strong).

Initiate treatment with high-dose glucocorticoids and cyclophosphamide or rituximab for severe GPA, transitioning to maintenance therapy with rituximab or mycophenolate mofetil to prevent relapse 4 6 8 (Evidence: Strong).

Monitor ANCA titers and clinical symptoms regularly to guide adjustments in immunosuppressive therapy 4 (Evidence: Moderate).

Consider multidisciplinary approaches for managing atypical presentations or complications in GPA, such as parotid gland involvement or severe cutaneous manifestations 8 12 14 (Evidence: Moderate).

References

1 Kaya Akca U, Batu ED, Jelusic M, Calatroni M, Bakry R, Frkovic M et al.. Comparison of EULAR/PRINTO/PReS Ankara 2008 and 2022 ACR/EULAR classification criteria for granulomatosis with polyangiitis in children. Rheumatology (Oxford, England) 2024. link 2 Webb H, Toppi J, Fairley J, Phillips D. Granulomatosis with Polyangiitis: A Rare but Clinically Important Disease for the Otolaryngologist. Nigerian journal of clinical practice 2024. link 3 Labrador AJP, Valdez LHM, Marin NRG, Ibazetta KAR, Chacón JAL, Fernandez AJV et al.. Oral granulomatosis with polyangiitis a systematic review. Clinical and experimental dental research 2023. link 4 Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A et al.. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. Arthritis & rheumatology (Hoboken, N.J.) 2022. link 5 Banerjee P, Kumar U, Khetarpal P, Senapati S. Meta-analysis confirmed genetic susceptibility conferred by multiple risk variants from CTLA4 and SERPINA1 in granulomatosis with polyangiitis. International journal of rheumatic diseases 2022. link 6 Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A et al.. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Annals of the rheumatic diseases 2022. link 7 Philip R, Dumont A, Martin Silva N, de Boysson H, Aouba A, Deshayes S. ANCA and anti-glomerular basement membrane double-positive patients: A systematic review of the literature. Autoimmunity reviews 2021. link 8 Verma S, Joshi R, Shah R. Acne fulminans in a young man with granulomatosis with polyangiitis (Wegener's granulomatosis): A chance association or marker of serious systemic disease?. Indian journal of dermatology, venereology and leprology 2020. link 9 Jamali Moghadam SR, Salehi MR, Mojtahedi SY, Fadaei N, Dadras O, SeyedAlinaghi S et al.. Granulomatosis with Polyangiitis (GPA) in a 15-year-old Girl with Facial Acne-like Ulcers: A Case Report. Infectious disorders drug targets 2020. link 10 Yoo J, Kim HJ, Ahn SS, Jung SM, Song JJ, Park YB et al.. The utility of the ACR/EULAR 2017 provisional classification criteria for granulomatosis with polyangiitis in Korean patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clinical and experimental rheumatology 2018. link 11 Kim WK, Kim JB. Granulomatosis With Polyangiitis Involving the Ascending Aorta. The Annals of thoracic surgery 2018. link 12 Dosal J, Good E, Alshaiji J, De Solo S, Ricotti C, Alvarez-Connelly E. Hemorrhagic acneiform lesions in a teenager as the initial presentation of granulomatosis with polyangiitis. Pediatric dermatology 2014. link 13 Conn H, Green WR, de la Cruz ZC, Hillis A. Scleropachynsis maculopathy. Archives of ophthalmology (Chicago, Ill. : 1960) 1982. link 14 Scott E, Gullane PJ, Slinger RP. An unusual lesion presenting as a parotid tumor. The Journal of otolaryngology 1980. link

Granulomatosis with polyangiitis